TORONTO, Aug. 4, 2021 /CNW/ - HLS Therapeutics Inc. ("HLS"
or the "Company") (TSX: HLS), a pharmaceutical company focused on
central nervous system and cardiovascular markets, announces that
Gilbert Godin, CEO, and Tim Hendrickson, CFO, will present at the
Canaccord Genuity 41st Annual Growth Conference on Thursday August 12, 2021 at 11:00 a.m. Eastern Daylight Time. The
conference will be held in a virtual meeting format.
An audio webcast of the Company's presentation will be available
To register for the conference and schedule a one-on-one meeting
with HLS, please contact your representative at Canaccord
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a
pharmaceutical company focused on the acquisition and
commercialization of late-stage development, commercial stage
promoted and established branded pharmaceutical products in the
North American markets. HLS's focus is on products targeting the
central nervous system and cardiovascular therapeutic areas. HLS's
management team is composed of seasoned pharmaceutical executives
with a strong track record of success in these therapeutic areas
and at managing products in each of these lifecycle stages. For
more information, please visit: www.hlstherapeutics.com
SOURCE HLS Therapeutics Inc.